Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELL-ATTACK 1: Anti-CD19 CAR-T Cells for Severe Autoimmune Rheumatic Diseases
NCT07544225Phase 1Not yet recruiting
- Sponsor
- Gustave Roussy
- Start
- Dec 2026
- Primary completion
- Feb 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 CAR-T cells in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjögren's syndrome and 2 more, sponsored by Gustave Roussy. Primary endpoint: Unacceptable toxicities at 4 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)Sjögren's syndromesystemic sclerosis (SSc)idiopathic inflammatory myopathies (IIM)
Beyond the preview
Go deeper on NCT07544225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07544225.